NCT03637556 - Pilot Study to Assess the Safety, PK and Iron Chelating Activity of DST-0509 (Deferasirox) in Thalassemia Patients Refractory to Chelation | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 20, 2019

Primary Completion Date

June 8, 2021

Study Completion Date

August 16, 2021

Conditions

Thalassemia Major

Interventions

DRUG

DST-0509

Novel iron chelator with improved absorption characteristics

DRUG

Jadenu

Commercial iron chelator with standard absorption characteristics

DRUG

Exjade

Commercial iron chelator with standard absorption characteristics

Trial Locations (4)

Weill Cornell Medicine, New York-Presbyterian Hospital, New York

King Chulalongkorn Memorial Hospital, Bangkok

Thalassemia Center Faculty of Medicine Siriraj Hospital, Bangkok

Maharaj Nakorn Chiang Mai Hospital, Chiang Mai